2019
DOI: 10.1111/jcmm.14812
|View full text |Cite
|
Sign up to set email alerts
|

Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer

Abstract: Gastric cancer (GC) is a common malignancy with low 5-year overall survival (OS).Recently, immune therapy has been used to treat cancer. B7H5 and CD28H are novel immune checkpoint molecules. However, the prognostic value of B7H5/CD28H expression in patients with GC remains unclear. In this study, seventy-one patients diagnosed with GC were included in this study. Patients' GC tissues and matched adjacent tissue constructed a tissue microarray. The expression levels of B7H5 and CD28H were examined using immunoh… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
24
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 14 publications
(25 citation statements)
references
References 27 publications
(73 reference statements)
0
24
1
Order By: Relevance
“…[ 36 , 37 ] However, the HHLA2/CD28H interaction can also co-stimulate T cell proliferation and cytokine production via the AKT pathway. [ 18 , 38 ] Therefore, HHLA2 may have dual immune functions depending on the immune environment, receptor engagement or blockade, or interaction with different receptors, which is similar to the other members of the B7 family, such as B7-H3 and B7x. [ 24 , 39 ] In view of the conflicting results shown in HHLA2 so far, continued research and further understanding of these pathways is urgently needed to understand the causes of these differences among different tumors, to provide new strategies for tumor immunotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…[ 36 , 37 ] However, the HHLA2/CD28H interaction can also co-stimulate T cell proliferation and cytokine production via the AKT pathway. [ 18 , 38 ] Therefore, HHLA2 may have dual immune functions depending on the immune environment, receptor engagement or blockade, or interaction with different receptors, which is similar to the other members of the B7 family, such as B7-H3 and B7x. [ 24 , 39 ] In view of the conflicting results shown in HHLA2 so far, continued research and further understanding of these pathways is urgently needed to understand the causes of these differences among different tumors, to provide new strategies for tumor immunotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…Surgery is the optimal treatment for patients with GC. However, the disease is often asymptomatic at early stage and always diagnosed in later stages characterized by invasion or metastasis ( Hu et al, 2020 ). The prognosis of unresectable GC is very poor, even targeted therapy for human epidermal growth factor receptor-2 (HER-2) makes an improved overall survival (OS) of less than 16 months ( Bang et al, 2010 ; Shen et al, 2013 ).…”
Section: Introductionmentioning
confidence: 99%
“…They showed an inverse correlation between OS rate and cytoplasmic VISTA expression at a high level in GC patients. In contrast, the five-year OS rate in GC patients with high nucleus VISTA expression is identical with GC patients, who have a low level of nucleus VISTA expression [ 144 ]. Oliveira et al revealed that the expression of VISTA is reduced in GC cell lines compared to normal gastric tissue through the methylation of promoter-like methylation of CpG sites at the 5′ end of the Vsir gene and/or overexpression of miR-125a-5p [ 145 ].…”
Section: B7-h5 (Vista)mentioning
confidence: 99%
“…Due to the existence of an association between VISTA and PD-L1 expression in patients with GC, the combination of VISTA and PD-L1 blocking antibodies might be practicable in the treatment of GC patients, considering that it was effective in mouse tumor models [ 146 ]. Since VSIG-3 has been discovered as a ligand for the VISTA, it is suggested that targeting the VSIG-3/VISTA pathway via blocking antibodies provides a new approach for the immunotherapy of GC [ 144 ]. Targeting B7 family members with blocking antibodies may limit treatment due to side effects in some patients with cancer.…”
Section: Treatment Of Gastric Cancer Base On B7 Family Inhibitionmentioning
confidence: 99%